PT - JOURNAL ARTICLE AU - Esther H. Lips AU - Tapsi Kumar AU - Anargyros Megalios AU - Lindy L. Visser AU - Michael Sheinman AU - Angelo Fortunato AU - Vandna Shah AU - Marlous Hoogstraat AU - Emi Sei AU - Diego Mallo AU - Maria Roman-Escorza AU - Ahmed A. Ahmed AU - Mingchu Xu AU - Wim Brugman AU - Karen Clements AU - Helen R. Davies AU - Liping Fu AU - Anita Grigoriadis AU - Timothy M. Hardman AU - Lorraine M. King AU - Marielle Krete AU - Petra Kristel AU - Michiel de Maaker AU - Carlo C. Maley AU - Jeffrey R. Marks AU - Brian Menegaz AU - Lennart Mulder AU - Frank Nieboer AU - Salpie Nowinski AU - Sarah Pinder AU - Jelmar Quist AU - Carolina Salinas-Souza AU - Michael Schaapveld AU - Marjanka K. Schmidt AU - Abeer M. Shaaban AU - Rana Shami AU - Mathini Sridharan AU - John Zhang AU - Hilary Stobart AU - Deborah Collyar AU - Serena Nik-Zainal AU - Lodewyk F.A. Wessels AU - E. Shelley Hwang AU - Nicholas N. Navin AU - Andrew Futreal AU - Alastair Thompson AU - Jelle Wesseling AU - Elinor J. Sawyer AU - on behalf of the Grand Challenge PRECISION consortium TI - Genomic profiling defines variable clonal relatedness between invasive breast cancer and primary ductal carcinoma <em>in situ</em> AID - 10.1101/2021.03.22.21253209 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.22.21253209 4099 - http://medrxiv.org/content/early/2021/03/26/2021.03.22.21253209.short 4100 - http://medrxiv.org/content/early/2021/03/26/2021.03.22.21253209.full AB - Pure ductal carcinoma in situ (DCIS) is being diagnosed more frequently through breast screening programmes and is associated with an increased risk of developing invasive breast cancer. We assessed the clonal relatedness of 143 cases of pure DCIS and their subsequent events using a combination of whole exome, targeted and copy number sequencing, supplemented by single cell analysis. Unexpectedly, 18% of all invasive events after DCIS were clonally unrelated to the primary DCIS. Single cell sequencing of selected pairs confirmed our findings. In contrast, synchronous DCIS and invasive disease (n=44) were almost always (93%) clonally related. This challenges the dogma that almost all invasive events after DCIS represent invasive transformation of the initial DCIS and suggests that DCIS could be an independent risk factor for developing invasive disease as well as a precursor lesion. Our findings support a paradigm shift that confirms a more complex role for DCIS than previously recognized, and that the future management of DCIS should take into account both the precursor and risk factor implications of this diagnosis.Competing Interest StatementHRD &amp; SNZ hold patent filings on algorithms for tumour classificationFunding StatementThis work was supported by Cancer Research UK and by KWF Kankerbestrijding (ref. C38317/A24043) and Breast Cancer Now (TAP379). EJS is funded by a Career Development and Innovation Cancer Award, Guys &amp; St Thomas Charity. TK is funded by a T32 Translational Genomics Fellowship. NNN is funded by RO1CA240526, RO1CA236864 and the single cell work was supported by the Single Cell Genomics CPRIT Core Facilities Grant (RP180684). ESH is funded by RFA-CA-17-035 (NIH), 1505-30497 (PCORI), BCRF 19-074 (BCRF), DOD BC132057 and R01 CA185138-01. SNZ is funded by a CRUK Advanced Clinician Scientist Fellowship (C60100/A23916) and supported by the NIHR Cambridge BRC. AG is funded by BCN KCL-Q3. AMS is funded by Birmingham CRUK Centre (C17422/A25154). JK, LK, TH, AF, DM, CM, TH are funded by RFA-CA-17-035 (NIH; Hwang). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:1. The Sloane project, a national audit of women with non-invasive neoplasia within the United Kingdom National Health Service Breast Screening Programme approved by the West Glasgow Ethics Committee 1 (REF 08/S0703/147) and the London - Queen Square Research Ethics Committee (19/LO/0648). 2. the Dutch DCIS cohort study, this is a nation-wide, population-based patient cohort derived from the Netherlands Cancer Registry (NCR), in which all women diagnosed with primary DICS between 1989 and 2004 were included, and has a median follow up time of 12 years 32. This cohort was linked to the nationwide network and registry of histology and cytopathology in the Netherlands (PALGA). The study was approved by the review boards of the NCR (ref. no. 12.281) and PALGA (ref.no. LZV990). This study was approved by the institutional review board of the Netherlands Cancer Institute under number CFMPB166, CFMPB393 and CFMPB688. 3. the Duke Hospital cohort, a hospital-based study of women (age 40-75 years) diagnosed with DCIS between 1998 and 2016, with a median follow up of 7.9 years. The study was approved by the Duke institutional review board (IRB approvals: Pro00054877, Pro00068646). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data presented in this article will be made available upon publication and are available upon request.